Related Experiment Video
Updated: Feb 16, 2026

Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
Medication History versus Point-of-Care Platelet Activity Testing in Patients with Intracerebral Hemorrhage
Matthew B Maas1, Andrew M Naidech1, Minjee Kim1
1Division of Stroke and Critical Care, Department of Neurology, Northwestern University, Chicago, Illinois.
A history of antiplatelet medication use is a better predictor of hematoma expansion and poor outcomes in intracerebral hemorrhage (ICH) patients than point-of-care (POC) testing. This finding aids in identifying high-risk patients for better management.
Area of Science:
- Neurology
- Hematology
- Clinical Medicine
Background:
- Intracerebral hemorrhage (ICH) is a severe neurological condition often associated with antiplatelet medication use.
- Predicting hematoma expansion and functional outcomes is crucial for managing ICH patients.
- Point-of-care (POC) testing offers rapid assessment of platelet activity, but its utility in ICH requires evaluation.
Purpose of the Study:
- To compare the predictive value of reduced platelet activity (via POC testing) versus a history of antiplatelet medication exposure for hematoma expansion and poor functional outcomes in ICH patients.
- To determine if POC measures of platelet function are superior to medication history in identifying patients at risk for adverse events after spontaneous ICH.
Main Methods:
- Prospective observational cohort study of patients with spontaneous ICH.
- Platelet activity measured on admission using PFA-100 and VerifyNow-ASA POC systems.
- Univariate and adjusted multivariate analyses to assess associations with hematoma growth (24 hours) and functional outcomes (modified Rankin Scale at 3 months).
Main Results:
- Antiplatelet medication history showed a stronger univariate association with hematoma growth than POC measures.
- In multivariable models, antiplatelet history remained significantly associated with hematoma growth (β 3.64, P=.007), especially in patients assessed within 6 hours (β 7.20, P<.001).
- Antiplatelet history, but not POC measures, was independently linked to poor functional outcomes (mRS 4-6) in the early (<6 hours) subgroup (aOR 3.6, P=.023).
Conclusions:
- A history of antiplatelet medication use is a more effective predictor of hematoma expansion and poor functional outcomes in spontaneous ICH patients compared to POC measures of platelet activity.
- These findings suggest that clinical history remains a vital tool in risk stratification for ICH.
- Further research may explore the specific role of POC testing in conjunction with clinical history for personalized ICH management.
Related Concept Videos
Patient-centered Care
What is Evolutionary History?
Life Histories
History of Microbiology
Inhaled Medications
Nursing Assessment of the Genitourinary System I: Health History

